Aim Egypt has the highest incidence of hepatitis C virus (HCV) infection in the world. Fibrosis development is common in HCV cases, and it is important in disease prediction. The aim of this study was to demonstrate the role of fibro scan in assessment of changes in hepatic stiffness in patients with chronic HCV infection following direct acting antiviral treatment (DAAT). Methods This prospective observational research included 120 patients with compensated HCV infection. All patients were subjected to fibro scan before and after receiving DAAT. Patients’ history, clinical examination, laboratory parameters (red – RBCs, and white blood cells - WBCs, hepatic function test, renal function test, coagulation profile, HBsAg, AFP - alpha feto protein, HbA1C, HCVAb) and fibro scan were done for all patients. Results Stiffness may differentiate F0-2 minimal fibrosis from F3-4 massive fibrosis using ROC-curve analysis, with 77.5% sensitivity, 90% specificity, 88.57% positive predictive value (PPV), and 80% negative predictive value (NPV). With sensitivity, specificity, PPV, and NPV of 71.4%, 44.5%, 43.48%, and 71.43%, respectively, the APRI-score can discriminate F0-2 from F3-4 at cutoff of 0.314. At a cutoff of 1.18, Fib4 calculation can discriminate F0-2 from F3-4, with sensitivity, specificity, PPV, and NPV of 78.6%, 64.1%, 63.04%, and 78.57%, respectively. Conclusion Hepatic fibrosis measurements such as fibro scan and non-invasive fibrosis scores (FIB-4) and aspartate aminotransferase (AST) to platelet ratio index (APRI) showed a significant improvement after direct-acting antiviral therapy. Improvements in hepatic function tests, serum creatinine level, and platelet count are also seen.
Wasitthankasem R, Vichaiwattana P, Siripon N, Posuwan N, Auphimai C, Klinfueng S, et al. Liver disease burden and required treatment expenditures for hepatitis C virus (HCV) infection in Thailand: implications for HCV elimination in the new therapeutic era, a population-based study. PLoS One. 2018;4(0196301).
2.
Naga M, Esmat E, Ahmed H, Abdel Samie R, Hamdy A, Naga Y. Clinical characteristics of HCV in Egyptian patients. EC Gastroenterolog DigSys. 2019;6:168–79.
3.
Kim JE, Ryoo BY, Ryu MH, Chang HM, Suh DJ, Lee HC, et al. Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function. Cancer Chemother Pharmacol. 2011;5:1285–90.
4.
Sumida Y, Nakajima A, Itoh Y. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol. 2014;20(475).
5.
Chin JL, Pavlides M, Moolla A, Ryan JD. Non-invasive markers of liver fibrosis: adjuncts or alternatives to liver biopsy. Frontiers Pharmacol. 2016;7(159).
6.
Ebrahim AE, Shehata MA, Abou-saif S, Abd-Elsalam S, Yousef M. Role of Fibroscan for early detection of hepatocellular carcinoma (HCC) in hepatitis C cirrhotic patients. Egyptian J Radio Nucl Med. 2020;51:1–6.
7.
Miller MM. Sofosbuvir–velpatasvir: A single-tablet treatment for hepatitis C infection of all genotypes. Americ J Health-Sys Pharm. 2017;74(1045).
8.
Ioannou GN, Feld JJ. What are the benefits of a sustained virologic response to direct-acting antiviral therapy for hepatitis C virus infection. Gastroenterol. 2019;156:446–60.
9.
Sebastiani G, Gkouvatsos K, Pantopoulos K. Chronic hepatitis C and liver fibrosis. World J Gastroenterol. 2014;20:11033–53.
10.
Castéra L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of transientelastography, Fibrotest, APRI, and liver biopsy for.
11.
the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005;128(343).
Liu CH, Lin JW, Tsai FC, Yang PM, Lai MY, Chen JH, et al. Noninvasive tests for the prediction of significant hepatic fibrosis in hepatitis C virus carriers with persistently normal alanine aminotransferases. Liver Intern. 2006;26:1087–94.
14.
Vallet‐Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin‐Venier V, et al. FIB‐4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology. 2007;46:32–6.
15.
Niro GA, Ciancio A, Gaeta GB, Smedile A, Marrone A, Olivero A, et al. Pegylated interferon alpha‐2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. Hepatology. 2006;43:713–20.
16.
Elbaz T, El-Kassas M, Esmat G. New era for management of chronic hepatitis C virus using direct antiviral agents: A review. J Advanc Res. 6(301).
17.
Bachofner JA, Valli PV, Kröger A, Bergamin I, Künzler P, Baserga A, et al. Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis‐4 score and aspartate aminotransferase‐platelet ratio index. Liver Internat. 2017;37:369–76.
18.
Saif-Al-Islam M, Abdelaal UM, Younis MA, Alghany Algahlan HA, Khalaf S. Effect of Direct-Acting Antiviral Therapy on Thrombocytopenic Patients with Hepatitis C Virus-Related Chronic Liver Disease. Gastroenterol Res Practic. 2021;2021.
19.
Mansour RH, Zaky S, El Kassas M, Mamdouh H, Esmat G. Evaluating the effect of direct-acting agents on liver fibrosis, by real-time elastography, Fibroscan and FIB4 score in chronic HCV patients. Sci J Al-Azhar Med Fac Girls. 2019;3:237–45.
20.
Gomaa A, Allam N, Elsharkway A, El Kassas M, Waked I. Hepatitis C infection in Egypt: prevalence, impact, and management strategies. Hepat Med. 2017;9(17).
21.
Elfiki MA, Farid M, Soliman A, Ibrahim BA. The effect of direct acting antiviral therapy for hepatitis C-virus infected Egyptian patients on changes in the parameters of liver fibrosis progression. Bulletin Egy Soci Physiol Sci. 2021;41:203–19.
22.
Elsharkawy A, Eletreby R, Fouad R, Soliman Z, Abdallah M, Negm M, et al. Impact of different sofosbuvir based treatment regimens on the biochemical profile of chronic hepatitis C genotype 4 patients. Expert Rev Gastroenterol hepatol. 2017;11:773–8.
23.
Mohammed AA, Attia D, Ebeid BA, Ibrahim MB. Study of the effect of direct acting antivirals (DAAs) on fibrosis in chronic hepatitis C patients using transient elastography. World J Adv Res Rev. 2021;10:135–45.
24.
Hsu WF, Lai HC, Su WP, Lin CH, Chuang PH, Chen SH, et al. Rapid decline of noninvasive fibrosis index values in patients with hepatitis C receiving treatment with direct-acting antiviral agents. BMC Gastroenterol. 2019;19:1–9.
25.
Deterding K, Höner Zu Siederdissen C, Port K, Solbach P, Sollik L, Kirschner J, et al. Improvement of liver function parameters in advanced HCV‐associated liver cirrhosis by IFN‐free antiviral therapies. Aliment Pharmacol Ther. 2015;42:889–901.
26.
Pons M, Santos B, Simón-Talero M, Ventura-Cots M, Riveiro-Barciela M, Esteban R, et al. Rapid liver and spleen stiffness improvement in compensated advanced chronic liver disease patients treated with oral antivirals. Therap Adv Gastroenterol. 2017;10:619–29.
27.
Holmberg SD, Lu M, Rupp LB, Lamerato LE, Moorman AC, Vijayadeva V, et al. Chronic Hepatitis Cohort Study (CHeCS) Investigators, Holmberg SD. Noninvasive serum fibrosis markers for screening and staging chronic hepatitis C virus patients in a large US cohort. Clinic Infect Dis. 2013;57:240–6.
28.
Sezaki H, Suzuki F, Hosaka T, Akuta N, Fujiyama S, Kawamura Y, et al. The efficacy and safety of dual oral therapy with daclatasvir and asunaprevir for genotype 1b in Japanese real‐life settings. Liver Internat. 2017;37:1325–33.
29.
Knop V, Mauss S, Goeser T, Geier A, Zimmermann T, Herzer K, et al. Dynamics of liver stiffness by transient elastography in patients with chronic hepatitis C virus infection receiving direct‐acting antiviral therapy Results from the German Hepatitis C‐Registry. J Viral Hepatitis. 2020;27:690–8.
30.
Tag-Adeen M, Sabra AM, Akazawa Y, Ohnita K, Nakao K. Impact of hepatitis C virus genotype-4 eradication following direct acting antivirals on liver stiffness measurement. Hepatic Medicine: Evidence Res. 2017;9(45).
31.
Ogasawara N, Kobayashi M, Akuta N, Kominami Y, Fujiyama S, Kawamura Y, et al. Serial changes in liver stiffness and controlled attenuation parameter following direct‐acting antiviral therapy against hepatitis C virus genotype 1b. J Med Virol. 2018;90:313–9.
32.
Yosry A, Fouad R, Alem SA, Elsharkawy A, ElSayed M, Asem N, et al. Role in prediction of fibrosis and response to therapy in Egyptian patients with HCV infection. Arab J Gastroenterol. 2016;17:78–83.
33.
Makhlouf NA, Farouk M, Nafeh HM, Hasanain AF, El-Mokhtar MA, Hetta HF, et al. NS34A resistance-associated substitutions in chronic hepatitis C in Upper Egypt and regression of liver fibrosis after direct-acting antiviral therapy. Egy Liver J. 2021;11:1–7.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
,
